Covagen AG (Covagen) is a biotechnology company engaged in the development of antibodies and protein based therapeutics for the treatment of inflammatory and oncology diseases. The company has developed its proprietary technology which help in isolation of Fynomers, a protein based binders to change the activities of the target molecules results in various diseases. Fynomers are small in size which helps in its administration not only through intravenous injection but also through other ways. The company has a dedicated research and development department which conducts research in Fyn SH3 domain which will replace the antibodies which are used for the treatment of several diseases such as rheumatoid arthritis and cancer. Covagen is headquartered in Zurich, Switzerland.